Leflunomide

Central Nervous System Neoplasm

PfizerSmall moleculePhase 3Dormant

BB

64/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 49/ 100
Competitive Position: 95/ 100

Competitive context

48 Active assets in the Central Nervous System Neoplasm cohort.

Asset / Sponsor	Phase	Rating
Procarbazine Universitätsmedizin Mannheim	Phase 3	BBB
Vincristine Sulfate Northwestern University	Phase 3	BBB
Irinotecan EpicentRx, Inc.	Phase 2	BBB
Gefitinib Memorial Sloan Kettering Cancer Center	Phase 2	BBB
Etoposide NewLink Genetics Corporation	Phase 3	BBB

View all 50 →

Same molecule, other indications

Leflunomide is also rated in:

immunoglobulin G4-related sclerosing diseaseDormant

BB

Indicative · Phase 4

69 / 100

plasma cell myelomaActive

BB

Indicative · Phase 2

64 / 100

smoldering plasma cell myelomaActive

B

Indicative · Phase 2

60 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.